Lund, Sweden June 30, 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announces that Hansa’s registered share capital and number of shares and votes have increased through (i) the issue of 10,550,000 new ordinary shares resolved on 19 June 2025 and registered with the Swedish Companies Registration Office on 24 June 2025, whereby the number of shares and votes increased with 10,550,000 and the share capital increased with SEK 10,550,000 and (ii) the set-off issue of 6,398,981 shares resolved upon on 19 June 2025 and registered with the Swedish Companies Registration Office on 24 June 2025, whereby the number of shares and votes increased with 6,398,981 and the share capital increased with SEK 6,398,981.

As of today, the total number of registered shares of Hansa amounts to 84,763,222, of which all are ordinary shares. As of today, the number of votes in Hansa amounts to 84,763,222, and the registered share capital amounts to SEK 84,763,222.

This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons below, on June 30, 2025 at 7:00 CEST.

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Stephanie Kenney, VP Global Corporate Affairs
[email protected]

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.